Citius Oncology (CTOR) Net Income towards Common Stockholders (2023 - 2026)
Citius Oncology (CTOR) reported Net Income towards Common Stockholders of -$8.92 million for fiscal Q3 2026 (quarter ended Jun 30, 2026), compared with -$5.37 million a year earlier.
Powered by 
Analysis
Citius Oncology (CTOR) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Citius Oncology's Net Income towards Common Stockholders came in at -$46.06 million; for FY2025 (ended Sep 30, 2025), it came in at -$24.76 million.
- By fiscal year, Net Income towards Common Stockholders came in at -$21.15 million in FY2024, $2.42 million in FY2023 (+535.3%), $380,811 in FY2022 and -$10,113 in FY2021.
- Five-year quarterly Net Income towards Common Stockholders spans a low of -$26.61 million in fiscal Q2 2026 and a high of $616,296 in fiscal Q2 2023.
- Per Business Quant data, the three fiscal quarters before Q3 2026 came in at -$26.61 million (Q2 2026), -$5.53 million (Q1 2026) and -$5 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Citius Oncology | 100.47 Mn | 100.47 Mn | 1.00 Mn | -8.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.92 Mn |
| Mar 31, 2026 | -26.61 Mn |
| Dec 31, 2025 | -5.53 Mn |
| Sep 30, 2025 | -5.00 Mn |
| Jun 30, 2025 | -5.37 Mn |
| Mar 31, 2025 | -7.74 Mn |
| Dec 31, 2024 | -6.66 Mn |
| Jun 30, 2024 | -4.77 Mn |
| Mar 31, 2024 | -4.84 Mn |
| Dec 31, 2023 | -4.73 Mn |
| Sep 30, 2023 | 157,943.00 |
| Jun 30, 2023 | 616,296.00 |
| Mar 31, 2023 | 611,725.00 |
API Access
Citius Oncology Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=CTOR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "CTOR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=CTOR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();